[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-neoplasms":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,85,125,151,182,204,227],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100643356","safety-and-performance-evaluation-of-the-ronovotm-robotic-surgical-platform-in-oncological-procedures-100643356",false,"NCT07632638","Safety and Performance Evaluation of the RonovoTM Robotic Surgical Platform in Oncological Procedures","Safety and Technical Evaluation of a Robotic Platform (RonovoTM) in Elective Oncological Surgery: A Prospective, Single-Arm, Multi-Specialty Registry","CONSTELAR","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Confirmed malignancy diagnosis\n3. Elective indication for robotic approach using RonovoTM\n4. Able to understand and sign informed consent\n\nExclusion Criteria:\n\n1. Formal contraindication to minimally invasive surgery\n2. Severe comorbidity prohibiting the procedure\n3. Refusal to participate or sign informed consent\n4. Emergency surgery","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","CONSTELAR is a prospective, single-arm, multi-specialty registry designed to evaluate the safety and intraoperative performance of the RonovoTM robotic surgical platform in adult patients undergoing elective oncological surgery. The study enrolls patients across four surgical specialties (Digestive Surgery, Thoracic Surgery, Urology, and Gynecology) at a single academic center. Primary endpoints include 30-day and 90-day complication rates (Clavien-Dindo classification), operative times, conversion rates, estimated blood loss, and device-related technical failures. Secondary endpoints encompass length of hospital stay, Intensive Care Unit (ICU) admission, readmission\u002Freoperation rates, and oncological surgical outcomes (resection margins, lymph node harvest). The study aims to provide initial safety and feasibility data to support the regulatory pathway for the RonovoTM platform in Latin America.",[27,28],"Malignant Neoplasms","Cancer",[30,31,32],"Robotic surgery","Minimally invasive surgery","Oncological surgery","RECRUITING","2026-07-01",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":37},"2026-06-19",{"date":41,"type":21},"2026-12",{"name":43,"class":44},"Instituto do Cancer do Estado de São Paulo","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100611765","phase-1-a-study-of-deg6498-in-participants-with-solid-tumors-100611765","NCT07244835","A Study of DEG6498 in Participants With Solid Tumors","A First in Human Phase 1 Open-Label, Multicenter, Dose Escalation and Expansion Study of DEG6498 in Patients With Solid Tumors","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent for the study prior to the performance of any study-specific procedures\n2. Male and female older than or equal to 18 years of age at the time signing the informed consent form (ICF)\n3. If female, must be postmenopausal, or surgically sterile, or agree to highly effective contraceptive measures to prevent pregnancy throughout treatment period and within 30 days of last study drug treatment\n4. Women of childbearing potential (WOCBP) must have 2 negative pregnancy tests (1 serum test required) as verified by the investigator prior to starting study drug\n5. If male, must agree to inform and ensure their female partners to use highly effective contraception measures to prevent pregnancy, and to refrain from donating sperm while on study drug and for at least 30 days following DEG6498 discontinuation\n6. Patients with advanced solid tumors, who have failed standard therapies, or for whom no standard therapy exists\n\n   1. Part 1: Advanced solid tumor patients\n   2. Part 2: Patients with BRAF mutation positive tumors and HCC\n7. Presence of at least 1 measurable lesion according to RECIST v1.1 .\n8. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nExclusion Criteria:\n\n1. Participant has a significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study, puts the participant at unacceptable risk if he\u002Fshe were to participate in the study\n2. Participant has a condition that confounds the ability for interpret data from the study\n3. Pregnant or breastfeeding women\n4. Active or concurrent malignancy requiring treatment (including both systemic therapy and radiotherapy) within 14 days or 5 half lives (whichever is shorter) prior to the first dose of study drug, or received antibody therapy within 28 days\n5. Symptomatic CNS metastases which are neurologically unstable, or CNS metastases requiring local CNS directed therapy, or increasing doses of corticosteroids within 2 weeks of first dose of study treatment.\n6. Clinically significant cardiovascular disease\n7. Known active or chronic infection that requires systemic therapy within 2 weeks of first dose of study drug\n8. Known human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome, or active HBV or HCV infection.",{"count":54,"type":21},100,[56],"PHASE1","The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors. It will also learn about DEG6498 pharmacokinetics (PK) profile and potential antitumor activity. The main questions it aims to answer are:\n\n* what is an appropriate dose to be given to participants?\n* are the side effects of treatment manageable?\n\nParticipants who are treated in this study will receive DEG6498 orally once a day and be closely monitored by the treating physicians.",[27],[60,61,62,63,64,65,66,67,68,69,70,71,72,73],"DEG6498","Solid tumor","Phase 1","BRAF mutation","Hepatocellular carcinoma (HCC)","Melanoma","Colorectal cancer (CRC)","Lung cancer","Thyroid cancer","Ovarian cancer","Pancreatic cancer","Glioblastoma","Renal cancer","Malignant peripheral nerve sheath tumor (MPNST)","2026-06-29",{"date":76,"type":37},"2026-06-30",{"date":78,"type":37},"2025-11-13",{"date":80,"type":21},"2028-12",{"name":82,"class":83},"Degron Therapeutics Co.","INDUSTRY",3,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":109,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100480603","phase-1-a-study-to-learn-about-the-study-medicine-called-pf-07799544-as-monotherapy-or-in-combination-in-people-with-advanced-solid-tumors-100480603","NCT05538130","A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors","A PHASE 1A\u002FB OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH BRAF-MUTANT MELANOMA AND OTHER SOLID TUMORS","Phase 1b Inclusion Criteria:\n\n* Diagnosis of advanced\u002Fmetastatic solid tumor (excluding colorectal cancer)\n* Measurable disease by RECIST version 1.1\n* Evidence of a BRAF V600 mutation\n* Prior therapy per tumor cohort\n* Adequate organ function per protocol\n\nPhase 1b Exclusion Criteria:\n\n* Other active malignancy within 3 years\n* Presence of leptomeningeal disease\n* History or current evidence of retinal vein occlusion (RVO) or history of retinal degenerative disease\n* Concurrent neuromuscular disorder associated with elevated creatine kinase (CK)\n* Active gastrointestinal disease as defined per protocol\n* History of interstitial lung disease as defined per protocol","16 Years",{"count":94,"type":21},124,[56],"The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with another study medicine called PF-07799933 (Phase 1b).\n\nPhase 1a is no longer open for enrollment. In Phase1b (noted as \"this study\"), we are seeking participants who have:\n\n* a solid tumor which is metastatic or recurrent (excluding colorectal cancer)\n* tumor with the mutation (abnormal gene) called \"BRAF V600\"\n* received required prior treatment for cancer per cohort assigned.\n\nAll participants in this study will receive both study medicines. Both study medicines are tablets that are taken by mouth at home twice a day.\n\nParticipants will receive study medicines until their cancer is no longer responding, unacceptable side effects, or 2 years. Participants may continue to receive study therapy beyond 2 years. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and effective.",[65,98,99,100,27,101,102,103,104,105,106,107,108],"Glioma","Thyroid Cancer","Non-Small Cell Lung Cancer","Brain Neoplasms","Advanced or Metastatic Solid Tumors","HGG","LGG","Low Grade Glioma","High Grade Glioma","Differentiated Thyroid Cancer","NSCLC (Non-small Cell Lung Cancer)",[110,111,112,113,114,115,116],"solid tumors","BRAF","advanced solid tumors","B-Raf","MAPK","neoplasms","BRAF V600",{"date":34,"type":37},{"date":119,"type":37},"2022-11-30",{"date":121,"type":21},"2029-06-18",{"name":123,"class":83},"Pfizer",83,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":135,"studyType":136,"phases":4,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":147,"leadSponsor":149,"locationsCount":4},"100644892","body-composition-and-setup-errors-in-radiotherapy-100644892","NCT07676032","Body Composition and Setup Errors in Radiotherapy","The Impact of Body Composition on Setup Errors in Patients Undergoing Radiotherapy With Thermoplastic Mask Immobilization: A Single-Center Prospective Cohort Study","BODY-SET","Inclusion Criteria:\n\n* Pathologically confirmed malignancy\n* Age ≥18 years\n* Receiving radical or adjuvant intensity-modulated radiotherapy (IMRT) with planned ≥25 fractions\n* Immobilized with thermoplastic mask\n* ECOG Performance Status 0-2\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Metal implants (pacemaker, artificial joints) affecting bioelectrical impedance analysis (BIA) measurements\n* Severe edema or ascites\n* Inability to cooperate with immobilization or CBCT scanning\n* Radiotherapy interruption \\>5 fractions\n* Pregnancy or lactation",{"count":134,"type":21},150,"1 Month","OBSERVATIONAL","This single-center prospective cohort study investigates the association between body composition parameters and setup errors in 120-150 patients receiving radiotherapy with thermoplastic mask immobilization. Body composition (skeletal muscle mass, body fat percentage, phase angle, fat-free mass) will be measured using bioelectrical impedance analysis at baseline and at fraction 20. Setup errors (six degrees of freedom) will be recorded via daily cone-beam computed tomography. The primary outcome is the association between baseline body composition and setup errors. Secondary outcomes include the relationship between body composition changes during radiotherapy and setup error evolution, and identification of threshold values for clinically significant setup error increases. This study will provide evidence on whether body composition-beyond BMI-predicts radiotherapy setup accuracy, potentially enabling personalized immobilization and image-guided strategies.",[27],[140,141,142],"Bioelectrical Impedance Analysis","Setup Errors","Radiotherapy","NOT_YET_RECRUITING","2026-06-23",{"date":76,"type":37},{"date":34,"type":21},{"date":148,"type":21},"2027-03-31",{"name":150,"class":44},"Shijiazhuang People's Hospital",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":158,"sex":17,"minAge":159,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":162,"conditions":163,"keywords":168,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":4,"leadSponsor":179,"locationsCount":45},"100060106","collection-of-serum-and-tissue-samples-from-patients-with-biopsy-proved-or-suspected-malignant-disease-100060106","NCT00026884","Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease","Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Diseases","* INCLUSION CRITERIA:\n* Individuals with biopsy-proven malignant disease\n* Individuals suspected of having a malignant disease\n* Individuals who have or are suspected of having an inherited genitourinary malignant disorder\n* Participants must be \\>= 2 years of age\n* A relative (related by blood) of an individual with a confirmed or suspected diagnosis of a malignant disease or an inherited genitourinary malignant disorder.\n* All participants and parents\u002Fguardians, for children younger than 18 years of age, must sign an informed consent document indicating their understanding of the investigational nature and the risks of this study before any protocol related studies are performed.\n\nEXCLUSION CRITERIA:\n\n-Individuals whose co-morbidities preclude surgical intervention.",true,"2 Years",{"count":161,"type":21},5950,"Selected individuals suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the initial visit and at periodic intervals during the course of the disease. These samples will be stored in the tissue bank of the Urologic Oncology Branch. Aliquots of malignant and normal tissue will be collected at the time of surgery and stored in the tissue bank, Urologic Oncology Branch, NCI. These materials will be used in the research efforts of the Urologic Oncology Branch, NCI....",[27,164,165,166,167],"Hereditary Neoplastic Syndromes","Kidney Cancer","Renal Cancer","Bladder Cancer",[169,170,171,172,173,174],"Serum","Collection of Tissue","Malignant Disease","Molecular Basis","Genome Sequencing","Natural History",{"date":176,"type":37},"2026-06-24",{"date":178,"type":37},"1998-03-12",{"name":180,"class":181},"National Cancer Institute (NCI)","NIH",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":190,"minAge":18,"maxAge":4,"enrollmentInfo":191,"targetDuration":159,"studyType":136,"phases":4,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":84},"100469562","a-multi-center-study-of-sexual-toxicities-after-radiotherapy-100469562","NCT05394428","A Multi Center Study of Sexual Toxicities After Radiotherapy","Novel Functional Anatomic and Biomarker Indices of Radiation-Induced Female Sexual Toxicities in a Multi-Center Cohort","STAR","Inclusion Criteria:\n\n* Patients with female sexual organs ages 18 and older.\n* Patients must meet at least one of the following two criteria:\n\n  * have been sexually active in the 36 months prior to initiating cancer treatment.\n  * have the intent to be sexually active in the 24 months following treatment..\n* Patients must be able to provide consent and be willing to participate.\n* Patients must have primary anal, rectal, cervical, uterine, vaginal, or vulvar cancer planned to receive pelvic radiotherapy.\\*\\* Patients must have an Eastern Cooperative Oncology Group performance status \\\u003C=2.\n\nExclusion Criteria:\n\n* planned for or undergone extensive pelvic surgery (e.g. pelvic exenteration, non-TME techniques, or surgeries otherwise affecting pudendal neurovasculature);\n* have clinically or radiologically detectable widespread metastasis;\n* have limited life expectancy due to comorbid disease;\n* have a personal history of cancer other than non-melanoma skin cancer in the last 5 years;\n* have contraindications or strong relative contraindications to radiotherapy at baseline as determined by the treating radiation oncologist (pregnancy, lactation, genetic susceptibility to cancer from ionizing radiotherapy, connective tissue disorders, inflammatory\u002Firritable bowel disease, history of prior pelvic radiotherapy).\n* have persistent, infectious gastroenteritis, colitis or gastritis;\n* have persistent or chronic diarrhea of unknown etiology; have recurrent or untreated GI infection (clostridium difficile or H. pylori);\n* have current or recurrent vaginal infection;\n* have current or recent antibiotic use (within 2 months).\n\nPatients may be enrolled regardless of previous local or systemic treatments received prior to enrollment in the STAR Study.\n\nPatients may be enrolled on the STAR Study concurrently with another study or clinical trial.","FEMALE",{"count":192,"type":21},300,"The purpose of this research is to understand how radiotherapy and other cancer treatments impact sexual function in female cancer patients and to try to answer a question about why some patients who receive radiotherapy are more likely to have side effects than others. The results of this study may improve our understanding of why sexual side effects occur and in turn develop predictive models and biomarkers of sexual side effects and other side effects that may impact sexual function. The results of this study may also lead to improvements in the techniques used to deliver radiotherapy or the development of interventions that will prevent or reduce sexual side effects and improve quality of life for female patients with cancer.",[27],"2026-06-18",{"date":197,"type":37},"2026-06-22",{"date":199,"type":37},"2022-10-04",{"date":201,"type":21},"2027-08-31",{"name":203,"class":44},"Icahn School of Medicine at Mount Sinai",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":215,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":45},"100642894","phase-1-phase-i-clinical-trial-of-ykyy031-for-injection-in-patients-with-advanced-solid-tumors-100642894","NCT07631793","Phase I Clinical Trial of YKYY031 for Injection in Patients With Advanced Solid Tumors","Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of YKYY031 for Injection in Patients With Advanced Solid Tumors","YKYY031，tumors","Inclusion criteria： Participants meeting all the following criteria may be enrolled\n\n1. Male or female patients aged 18 to 75 years old at the time of signing the informed consent form.\n2. Histologically or cytologically confirmed advanced or metastatic solid tumors that have failed standard therapy and have no effective treatment options, including but not limited to colorectal cancer, pancreatic cancer, etc.\n\n   For colorectal cancer (CRC) patients, prior receipt of at least second-line standard therapy failure and no effective treatment options; adjuvant\u002Fneoadjuvant chemotherapy failure during or within 6 months after the last treatment is considered first-line failure.\n\n   For pancreatic cancer patients, prior receipt of at least first-line standard therapy failure and no effective treatment options; adjuvant\u002Fneoadjuvant chemotherapy failure during or within 6 months after the last treatment is considered first-line failure.\n3. Patients must have human leukocyte antigen (HLA) subtype HLA-A\\*11:01.\n4. Patients must test positive for at least one of the tumor-specific antigens (TSA) targeted by YKYY031, including KRAS G12D, KRAS G12C, KRAS G12V, KRAS G13D, KRAS G12R, KRAS G12S, PIK3CA E542K, TP53 R248Q, PIK3CA E545K, BRAF V600E, PIK3CA H1047L, FBXW7 R465C.\n5. Eastern Cooperative Oncology Group (ECOG) performance status score: 0-1.\n6. Expected survival duration ≥ 3 months.\n7. At least one measurable lesion (non-nodal lesions with longest diameter ≥10 mm, nodal lesions with shortest diameter ≥15 mm) according to RECIST V1.1.\n8. Major organ function is good, meeting the following requirements:\n\n   Hemoglobin ≥90 g\u002FL, absolute neutrophil count ≥1.5×10⁹\u002FL, platelet count ≥80×10⁹\u002FL within 14 days prior to the first dose, without the use of hematopoietic growth factors, blood transfusions, blood products, albumin, or blood products.\n\n   Total bilirubin ≤1.5× upper limit of normal (ULN); if liver metastasis or Gilbert's syndrome is present, total bilirubin ≤3×ULN.\n\n   Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤3×ULN; if liver metastasis is present, ALT or AST ≤5×ULN.\n\n   Serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL\u002Fmin (calculated using the Cockcroft-Gault formula).\n\n   Prothrombin time ≤1.5×ULN (unless using warfarin anticoagulation). International normalized ratio (INR) ≤1.5×ULN (unless using warfarin anticoagulation).\n\n   Left ventricular ejection fraction (LVEF) ≥50% as assessed by cardiac Doppler ultrasound\u002FMUGA.\n9. Participants with childbearing potential or male participants must have no plans for conception, egg donation, or sperm donation from the date of signing the informed consent form until 6 months after the last study treatment, and must agree to use effective contraception (including one or more non-pharmacological contraceptive measures) or safety measures during this period.\n10. Agree to comply with all requirements and procedures of the clinical trial and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria will be excluded\n\n1. Allergy to the investigational product (including any excipients). History of severe allergy to any drug, food, or vaccine, such as anaphylactic shock, angioneurotic edema, allergic dyspnea, anaphylactoid purpura, thrombocytopenic purpura, Arthus reaction, etc.\n2. History of other malignancies, except for cured skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, etc., that have not recurred within 5 years prior to screening, as judged by the investigator to be eligible for enrollment.\n3. Symptomatic central nervous system metastasis or meningeal metastasis, or other evidence indicating uncontrolled central nervous system metastasis or meningeal metastasis, as judged by the investigator to be unsuitable for enrollment. Patients with stable brain metastases (no imaging progression within 4 weeks, and not requiring corticosteroid treatment for at least 4 weeks before the first dose of the study drug) may be enrolled.\n4. Significant clinically significant cardiovascular diseases, including but not limited to:\n\n   1. Congestive heart failure (New York Heart Association \\[NYHA\\] class \\> II)\n   2. Myocardial infarction, unstable angina, severe pericardial disease, severe myocardial disease within the past 6 months\n   3. Need for treatment of valvular regurgitation or stenosis\n   4. Any supraventricular or ventricular arrhythmia requiring treatment or intervention; uncontrolled malignant arrhythmia; complete left bundle branch block, second- or third-degree atrioventricular block\n   5. QT interval (QTcF) \\>450 ms in males, \\>470 ms in females\n   6. Uncontrolled hypertension (defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg despite treatment with two or three antihypertensive agents)\n5. Any active autoimmune disease or history of autoimmune disease, including but not limited to immunologically related neurological diseases, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barré syndrome, myasthenia gravis, systemic lupus erythematosus, connective tissue disease, scleroderma, autoimmune hepatitis, toxic epidermal necrolysis, or Stevens-Johnson syndrome (except for type 1 diabetes mellitus on a stable dose of insulin, hypothyroidism on stable hormone replacement therapy, etc.).\n6. Any uncontrolled clinical disease (e.g., respiratory, circulatory, neurological, hematological, genitourinary, endocrine system diseases) or psychiatric disease (e.g., depression, schizophrenia) or other major illness, as judged by the investigator to interfere with providing informed consent, interpretation of trial results, participation in the trial posing risks to the participant, or otherwise affecting the achievement of trial objectives, including uncontrolled pleural effusion, pericardial effusion, or ascites as judged by the investigator.\n7. Known history of interstitial pneumonia or high suspicion of interstitial pneumonia; or presence of pulmonary abnormalities that may interfere with the detection or management of suspected drug-related pulmonary toxicity during the trial.\n8. Any abnormality at the injection site that, as judged by the investigator, would hinder observation of local reactions at the injection site.\n9. Presence of contraindications to intramuscular injection.\n10. Received any antitumor therapy (including chemotherapy, targeted therapy, immunotherapy, etc.) or participated in another drug or device clinical trial within 4 weeks or 5 half-lives (whichever is shorter) prior to the first dose; received traditional Chinese medicine or patent Chinese medicine with clear antitumor indications within 2 weeks prior to the first dose.\n11. Previous antitumor treatment-related adverse events that have not recovered to ≤ grade 1 according to CTCAE, except for toxicities judged by the investigator to have no safety risk, such as alopecia, grade 2 peripheral neurotoxicity, hypothyroidism stabilized by hormone replacement therapy, etc.\n12. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation.\n13. Use of corticosteroids (\\>10 mg\u002Fday prednisone or equivalent other glucocorticoids) or other immunosuppressants for systemic treatment within 14 days prior to the first dose of the vaccine. Inhaled or topical steroids and adrenal hormone replacement at doses ≤10 mg\u002Fday prednisone are allowed in the absence of active autoimmune disease.\n14. Received live\u002Fattenuated live\u002Finactivated vaccines within 4 weeks prior to the first dose of the vaccine.\n15. Prior receipt of a therapeutic tumor vaccine targeting the same antigen.\n16. Bleeding disorders (e.g., coagulation factor deficiency, coagulation dysfunction \\[as judged by the investigator to be unsuitable for enrollment\\]), or a history of significant bruising or bleeding after injection or blood draw.\n17. Blood donation or significant blood loss (\\>450 mL) within 3 months prior to screening, or planned blood or blood component donation during the study period.\n18. Major surgery within 4 weeks prior to screening (minor procedures such as catheter placement and biopsy required by the protocol are not exclusionary), or unresolved effects of surgery or trauma within 14 days prior to enrollment.\n19. History of substance abuse or known medical, psychological, or social conditions, such as alcoholism or drug addiction.\n20. Positive human immunodeficiency virus antibody test result, active syphilis (defined as positive syphilis antibody test and positive reagin test), active hepatitis B (defined as hepatitis B virus \\[HBV\\] DNA ≥2000 IU\u002FmL), or active hepatitis C (defined as hepatitis C virus \\[HCV\\] RNA test positive).\n21. Active tuberculosis (TB) (patients suspected of having active TB require further consultation with the infectious disease department for definitive diagnosis) or history of active TB; or severe acute or chronic infection requiring systemic treatment.\n22. Pregnant or breastfeeding women.\n23. Any other condition deemed by the investigator to make the participant unsuitable for participation in this trial.","75 Years",{"count":214,"type":21},76,[56],"Phase I study of YKYY031 for injection in patients with advanced solid tumors",[27],"2026-06-01",{"date":220,"type":37},"2026-06-08",{"date":222,"type":21},"2026-05-30",{"date":224,"type":21},"2030-12-07",{"name":226,"class":83},"Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":17,"minAge":233,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":45},"100629056","phase-2-an-open-label-randomized-phase-2-clinical-trial-to-evaluate-the-efficacy-and-safety-of-the-combination-therapy-of-slc-3010-and-axitinib-compared-to-axitinib-monotherapy-as-a-second-line-treatment-for-locally-advanced-or-metastatic-clear-cell-renal-cell-carcinoma-100629056","NCT07469683","An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed diagnosis of locally advanced or metastatic ccRCC.\n\n   1. Part 1 (Safety Run-in): At least one first-line treatment of standard of care in the recurrent\u002Fmetastatic setting.\n   2. Part 2 (Phase 2): Anti-PD-1 (Programmed Cell Death Protein 1) or anti-PD-L1 (Programmed Cell Death-Ligand 1) monotherapy or combination therapy as first-line treatment in the recurrent\u002Fmetastatic setting.\n2. At least one measurable lesion as defined by RECIST (Response Evaluation Criteria in Solid Tumors) v1.1.\n3. Male or female patients aged ≥ 19 years at the date on which the informed consent is signed.\n4. Ability and willingness to provide written informed consent and to comply with all study procedures.\n5. Estimated life expectancy of ≥ 3 months.\n6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.\n7. Adequate organ functions as defined below. System organ class Laboratory test results\n\n   \\- Hematology\n\n   : Absolute neutrophil count (ANC) ≥ 1500 cells\u002FμL without the support of granulocyte colony-stimulating factor (G-CSF) within 2 weeks prior to the first dose of the study intervention.\n\n   Platelet count ≥ 100,000\u002FμL without the support of transfusion within 2 weeks prior to screening laboratory sample collection.\n\n   Hemoglobin ≥ 9 g\u002FdL without the support of transfusion within 2 weeks prior to screening laboratory sample collection.\n   * Coagulation\n\n     :International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 × the upper limit of normal (ULN). If the patient is receiving anticoagulant therapy, PT shall be within the therapeutic range for the intended use of anticoagulants.\n   * Kidney\n\n     :Estimated glomerular filtration rate (eGFR) calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. ≥ 40 mL\u002Fmin\u002F1.73 m2\n   * Liver :Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for patients with Gilbert's syndrome), or if total bilirubin is \\> 1.5 × ULN, direct bilirubin ≤ ULN.\n\n   Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (≤ 5 × ULN for patients with documented liver metastases).\n\n   Albumin ≥ 2.8 g\u002FdL\n8. If there were any clinically significant toxicities from prior therapies, they shall have resolved to Grade 0 or Grade 1 according to the NCI CTCAE v5.0 (Alopecia and ≤ Grade 2 endocrine-related adverse events related to prior immunotherapy (e.g., immune checkpoint inhibitors) that require medical treatment or hormone replacement therapy are considered acceptable for study participation.).\n9. Male and female patients of childbearing potential shall agree to use existing, highly effective contraception methods with the failure rate of \\\u003C1% (Appendix 1) during the treatment period and for 3 months after the last administration of the study intervention. Acceptable methods shall include barrier methods such as spermicide condoms or diaphragms. Women of childbearing potential (WOCBP) are defined as females who have experienced menarche and are not postmenopausal (including amenorrhea for at least 2 years without hormone therapy or surgical sterilization).\n10. WOCBP shall have a documented negative serum or urine pregnancy test at screening, performed within 3 days prior to the first administration of the study intervention. For non-childbearing females, one of the following shall be documented:\n\n    1. Postmenopausal status, defined as the absence of regular menstruation for at least 12 consecutive months with a documented serum follicle-stimulating hormone (FSH) level within the laboratory reference range for postmenopausal women, or\n    2. Documented history of hysterectomy or bilateral oophorectomy, or\n    3. Medically confirmed ovarian failure.\n\nExclusion Criteria:\n\n1. History of malignancy or active malignancy other than the target disease in this study. Exceptions are as follows:\n\n   1. Malignancies that have been treated with curative intent and have not recurred within the recent 2 years.\n   2. Completely resected basal cell carcinoma or squamous cell carcinoma of the skin.\n   3. Any type of completely resected carcinoma in situ.\n2. Known brain metastases or epidural conditions. However, patients who have been sufficiently treated with radiotherapy and\u002For surgery (including radiosurgery) and have been stable for at least 4 weeks prior to the first administration of the study intervention can be enrolled. Note: Patients with an incidental finding of a single lesion \\\u003C1 cm may be eligible if deemed not to require treatment at the discretion of the investigator. Eligible patients shall be neurologically asymptomatic and shall not have received corticosteroid therapy for at least 2 weeks prior to the first administration of the study intervention.\n3. Diagnosis of immunodeficiency or current use of chronic systemic corticosteroids or other immunosuppressive therapy within 7 days prior to the first administration of the study intervention. Topical (\\\u003C Grade III), inhaled corticosteroids, or intra-articular corticosteroids, topical creams\u002Flotions, mouthwashes containing corticosteroids, or mineralocorticoids (e.g., fludrocortisone) are allowed.\n\n   Note: Chronic use of ≤ 10 mg\u002Fday of prednisone or equivalent may be allowed after discussion and approval by the lead institution.\n4. Active autoimmune disease that has required systemic treatment (e.g., disease controllers, corticosteroids, or immunosuppressive drugs) within the recent 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal insufficiency or hypopituitarism) is not considered a form of systemic treatment.\n5. Known infection with Human Immunodeficiency Virus-1 (HIV-1) or HIV-2. Known active hepatitis B virus infection (i.e., HBsAg positive) or hepatitis C virus infection (e.g., \\[qualitatively\\] detectable HCV RNA). Patients with a negative HCV RNA test after a positive HCV antibody test and no ongoing anti-HCV therapy.\n6. Active infection requiring systemic therapy.\n7. Significant cardiovascular diseases, including but not limited to: Stable arrhythmias medically controlled with ongoing medication are allowed.\n\n   1. QT interval (Interval from the start of the Q wave to the end of the T wave of the ECG) corrected for heart rate using Fridericia's formula (QTcF) \\> 480 msec at screening\n   2. Myocardial infarction, acute coronary syndrome, or history of coronary angioplasty\u002Fstenting\u002Fbypass grafting within the recent 6 months.\n   3. Congestive heart failure (CHF) classified as New York Heart Association (NYHA) Class II-IV, or a history of NYHA Class III or IV CHF.\n8. Patients with significant respiratory symptoms, known or suspected serious or severe pulmonary conditions at screening, or requiring supplemental oxygen.\n9. Any form of systemic anticancer therapy (including investigational therapy) within 3 weeks prior to the first administration of the study intervention, or within 5 half-lives of the drug if known, whichever is shorter.\n10. Participation in an interventional clinical trial involving an investigational drug or device within 3 weeks prior to the first administration of the study intervention in this clinical trial. Patients who are participating in follow-up may be enrolled if more than 3 weeks have passed since the last administration.\n11. Radiotherapy within 2 weeks prior to the first administration of the study intervention. Patients with ongoing clinically related complications from prior radiotherapy are not eligible.\n12. Major surgery within 2 weeks prior to administration of the study intervention. Patients shall have sufficiently recovered from any toxicity and\u002For complications at the discretion of the investigator.\n13. Live vaccine administration within 4 weeks prior to the first administration of the study intervention. Administration of non-live COVID-19 vaccines within 7 days prior to the DLT assessment is contraindicated, as vaccine-related toxicity may interfere with safety assessments.\n14. Prior therapy using IL-2 (interleukin-2)-based drugs.\n15. History of prior axitinib treatment.\n16. Inability to swallow oral drugs or presence of gastrointestinal disorders that may affect absorption (e.g., gastrectomy, partial bowel obstruction, or malabsorption syndrome).\n17. Current administration of potent CYP3A4 inducers (e.g., mitotane, phenytoin, rifampin, carbamazepine, or St. John's Wort) that cannot be discontinued during the study.\n18. Current administration of potent CYP3A4 inhibitors (e.g., boceprevir, cobicistat, itraconazole, ketoconazole, clarithromycin, idelalisib, nefazodone, nelfinavir, and ritonavir co-administered with protease inhibitors) that cannot be discontinued during the study.\n19. Medically significant bleeding within 3 months prior to randomization. Tumor invasion\u002Finfiltration of major blood vessels shall be evaluated, and the potential risk of severe hemorrhage due to tumor shrinkage or necrosis will be considered as part of the exclusion assessment.\n20. Ongoing concomitant treatment at a therapeutic dose with anticoagulants such as heparin, thrombin, or factor Xa inhibitors, or with antiplatelet agents (e.g., clopidogrel).\n\n    1. Low-dose aspirin (≤ 100 mg\u002Fday), prophylactic low molecular weight heparin (LMWH), and prophylactic factor Xa inhibitors are acceptable.\n    2. Anticoagulation therapy with LMWH at a therapeutic dose is allowed in participants who have no radiologic evidence of uncontrolled brain metastases, have been on a stable dose of LMWH for at least 2 weeks prior to randomization, and have no history of thromboembolic complications or complications from anticoagulation therapy.\n21. Presence of the following clinically significant diseases:\n\n    1. Unhealed serious active wounds, ulcers, or fractures\n    2. Requirement for hemodialysis or peritoneal dialysis.\n    3. History of solid organ transplantation.\n    4. Ascites with symptoms requiring medical intervention.\n22. Known hypersensitivity to any component of the study intervention (SLC-3010 or axitinib), or their analogs.\n23. Any condition, therapy, laboratory abnormality, or other circumstance (medical history or current evidence) that may expose the patient to risk by participating in the clinical trial, cause confusion in study results, or interfere with the patient's participation throughout the study.\n24. Psychiatric or substance abuse disorders known to interfere with compliance with study requirements.\n25. For female patients only: Pregnant or breastfeeding.","19 Years",{"count":235,"type":21},78,[237],"PHASE2","\"This study is a phase 2, randomized study to evaluate the efficacy and safety of SLC-3010 in combination with axitinib versus axitinib monotherapy as second-line treatment in patients with locally advanced or metastatic clear cell renal cell carcinoma (ccRCC).\n\nThis study includes a screening period, a treatment period, and a follow-up period. All patients will complete a screening period of up to 28 days. During the treatment period, patients will receive either SLC-3010 in combination with axitinib or axitinib monotherapy. Treatment may continue until the occurrence of unacceptable toxicity related to the study intervention, patient refusal for further participation, or disease progression.\n\nThe patients will be followed up for disease progression and survival for up to 2 years after discontinuation of the study intervention, or until death, consent withdrawal, or the end of this clinical trial, whichever occurs first. For patients who withdraw consent, survival will be followed up via telephone or site visits every 2 months up to death or 12 months after the first administration of the last patient, whichever occurs first, depending on their consent for follow-up.\n\nThis study consists of two parts: Part 1 is the safety run-in phase for SLC-3010 in combination with axitinib, and Part 2 is a randomized phase 2 trial to compare SLC-3010 in combination with axitinib and axitinib monotherapy.",[240,241,27,242],"Clear Cell Renal Cell Carcinoma","Neoplasms","Malignant Neoplasm of Kidney, Except Renal Pelvis","2026-03-10",{"date":245,"type":37},"2026-03-13",{"date":247,"type":21},"2026-03",{"date":249,"type":21},"2029-10",{"name":251,"class":44},"Yonsei University"]